American Heart Journal
Volume 154, Issue 1 , Pages 12-38 , July 2007

Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: The IMPROVE HF performance improvement registry

  • Gregg C. Fonarow, MD

      Affiliations

    • Department of Medicine, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Gregg C. Fonarow, MD, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, 10833 LeConte Avenue, Room 47-123 CHS, Los Angeles, CA 90095-1679.
    • ,
  • Clyde W. Yancy, MD

      Affiliations

    • Department of Medicine, University of Texas, Southwestern Medical Center, Dallas, TX (currently Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX)
    • ,
  • Nancy M. Albert, PhD, RN

      Affiliations

    • Division of Nursing and George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Anne B. Curtis, MD

      Affiliations

    • Division of Cardiology, University of South Florida College of Medicine, Tampa, FL
    • ,
  • Wendy Gattis Stough, PharmD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, NC
    • Department of Clinical Research, Campbell University School of Pharmacy, Research Triangle Park, NC
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL
    • ,
  • J. Thomas Heywood, MD

      Affiliations

    • Division of Cardiology, Scripps Clinic, La Jolla, CA
    • ,
  • Mandeep Mehra, MD

      Affiliations

    • Division of Cardiology, University of Maryland, Baltimore, MD
    • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Division of Cardiology, Duke University Medical Center, Durham, NC
    • ,
  • Dwight Reynolds, MD

      Affiliations

    • Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK
    • ,
  • Mary Norine Walsh, MD

      Affiliations

    • The Care Group, LLC, Indianapolis, IN

Received 16 March 2005 ,Accepted 18 March 2007.

References 

  1. American Heart Association . Heart Disease and Stroke Statistics—2007 update. Dallas (TX): American Heart Association; 2007;
  2. American Heart Association . Heart Disease and Stroke Statistics—2006 Update. Dallas (TX): American Heart Association; 2006;
  3. Heart Failure Society of America . Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. J Card Fail. 1999;5:357–382
  4. Bonow RO, Bennett S, Casey DE, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2005;46:1144–1178
  5. Hunt SA, Abraham WT, Chin MH, et al. In: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Web site; 2005;p. 1–82
  6. Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation. 2004;110:3518–3526
  7. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation. 2006;113:799–805
  8. Shahar E, Lee S, Kim J, et al. Hospitalized heart failure: rates and long-term mortality. J Card Fail. 2004;10:374–379
  9. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703–712
  10. Adams KF, Lindenfeld J, Arnold JMO, et al. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–e122
  11. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  12. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  13. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289:2685–2694
  14. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  15. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549
  16. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–1853
  17. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43–51
  18. Fonarow GC. Strategies to improve the use of evidence-based heart failure therapies: OPTIMIZE-HF. Rev Cardiovasc Med. 2004;5:S45–S54
  19. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240–1247
  20. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56–61
  21. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 2005;165:1469–1477
  22. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002;360:1631–1639
  23. Ansari M, Shlipak MG, Heidenreich PA, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation. 2003;107:2799–2804
  24. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635–2645
  25. Silagy CA, Weller DP, Lapsley H, et al. The effectiveness of local adaptation of nationally produced clinical practice guidelines. Fam Pract. 2002;19:223–230
  26. Cranney M, Warren E, Barton S, et al. Why do GPs not implement evidence-based guidelines? A descriptive study. Fam Pract. 2001;18:359–363
  27. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness—which ones work? Meta-analysis of published reports. BMJ. 2002;325:925
  28. Spertus JA, Eagle KA, Krumholz HM, et al. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. J Am Coll Cardiol. 2005;45:1147–1156
  29. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101–2113
  30. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450–1456
  31. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602–1609
  32. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  33. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184–1191
  34. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717
  35. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  36. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001;104:2118–2150
  37. Shivkumar K, Jafri SM, Gheorghiade M. Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial. Prog Cardiovasc Dis. 1996;38:337–342
  38. Brook RH, McGlynn EA, Shekelle PG. Defining and measuring quality of care: a perspective from US researchers. Int J Qual Health Care. 2000;12:281–295
  39. Joint Commission on Accreditation of Healthcare Organizations . Facts about ORYX for hospitals, core measures and hospital core measures. 2006;Available at www.jointcommission.org/AccreditationPrograms/Hospitals/ORYX/oryx_facts.htm
  40. Brook RH, McGlynn EA, Cleary PD. Quality of health care. Part 2: measuring quality of care. N Engl J Med. 1996;335:966–970
  41. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049–1060
  42. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA. 2002;287:1269–1276
  43. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol. 2005;46:1242–1248
  44. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA. 1998;279:1351–1357
  45. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  46. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–2226
  47. Toma M, McAlister FA, Ezekowitz J, et al. Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. Am J Cardiol. 2006;97:882–885
  48. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810–819
  49. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med. 2001;161:2223–2228
  50. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–1195
  51. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  52. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82–e293

 This registry is supported by Medtronic, Inc, Minneapolis, MN.

 The IMPROVE HF registry and this study are sponsored by Medtronic, Inc. The IMPROVE HF registry was established by Medtronic, Inc, under the guidance of a steering committee of academic advisors, each of whom is an author on this manuscript. The financial disclosures of the IMPROVE HF steering committee members are given below. These academic advisors were intimately involved in the initial preparation and design of this registry. Medtronic, Inc, provided financial and material support for the IMPROVE HF registry. A contract research organization, Outcome Sciences, Inc (Cambridge, MA), independently performs the practice site chart abstractions for IMPROVE HF and is responsible for performing data checks, storing site-specific and aggregate data, as well as providing benchmarked quality of care reports to practice sites. The contract research organization receives funding from Medtronic, Inc. Identified, individual practice site data are not shared with either the steering committee or the sponsor. The authors had complete control and authority over the study design, the manuscript preparation, and the decision to submit this manuscript to the American Heart Journal for publication. The manuscript was submitted to Medtronic, Inc, prior to submission for publication.

PII: S0002-8703(07)00254-2

doi: 10.1016/j.ahj.2007.03.030

American Heart Journal
Volume 154, Issue 1 , Pages 12-38 , July 2007

Article Tools

* Image Usage & Resolution